Skip to content
MatchScript
Menu

Head-to-head · The Match Score

ShedRx vs Coivas

Both scored on the same six-factor Match Score. ShedRx wins this matchup with a 86 to 63 edge.

Higher Match Score

ShedRx

#4 · Grade B+

People who want an oral or sublingual option rather than weekly injections.

Visit ShedRx
VS

Coivas

#237 · Grade C

People who want all-inclusive compounded GLP-1 pricing with a money-back guarantee.

Visit Coivas

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
84
68
Speed to Start
84
72
Formulary Match
92
66
Support Level
86
82
Flexibility
88
20
Transparency
82
72

Price, coverage & formulary

DetailShedRxCoivas
Semaglutide$199/mo$149/mo (quarterly plan, compounded)
Tirzepatide$299/mo$229/mo (quarterly plan, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjectable only
Match Score86 · B+63 · C
Winner: ShedRx

ShedRx edges out Coivas, 86 to 63 on the default Match Score. A weight-focused program that also offers an oral/sublingual route for the needle-averse.

Coivas is still a fair pick if its strengths line up with yours — best for: People who want all-inclusive compounded GLP-1 pricing with a money-back guarantee.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full ShedRx reviewFull Coivas review

More head-to-heads

Or browse alternatives to ShedRx and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.